JP2006506380A - 月経困難症の治療用トリアゾール化合物 - Google Patents

月経困難症の治療用トリアゾール化合物 Download PDF

Info

Publication number
JP2006506380A
JP2006506380A JP2004546268A JP2004546268A JP2006506380A JP 2006506380 A JP2006506380 A JP 2006506380A JP 2004546268 A JP2004546268 A JP 2004546268A JP 2004546268 A JP2004546268 A JP 2004546268A JP 2006506380 A JP2006506380 A JP 2006506380A
Authority
JP
Japan
Prior art keywords
triazol
benzyl
tetrahydro
bipyridinyl
ylmethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2004546268A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006506380A5 (enExample
Inventor
ダンカン アーマー，ロバート
ダグラス バクスター，アンドリュー
スティーブン ブライアンス，ジャスティン
ネイル ダック，ケビン
スティーブン ジョンソン，パトリック
アンドリュー ルースウェイト，ラッセル
ニューマン，ジュリー
ジェイムズ ローソン，デイビット
リックマンズ，トーマス
Original Assignee
ファイザー・インク
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ファイザー・インク filed Critical ファイザー・インク
Publication of JP2006506380A publication Critical patent/JP2006506380A/ja
Publication of JP2006506380A5 publication Critical patent/JP2006506380A5/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Otolaryngology (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Reproductive Health (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2004546268A 2002-10-25 2003-10-14 月経困難症の治療用トリアゾール化合物 Withdrawn JP2006506380A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0224919.1A GB0224919D0 (en) 2002-10-25 2002-10-25 Triazole compounds useful in therapy
PCT/IB2003/004587 WO2004037809A1 (en) 2002-10-25 2003-10-14 Triazole compounds for the treatment of dysmenorrhoea

Publications (2)

Publication Number Publication Date
JP2006506380A true JP2006506380A (ja) 2006-02-23
JP2006506380A5 JP2006506380A5 (enExample) 2006-11-30

Family

ID=9946618

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004546268A Withdrawn JP2006506380A (ja) 2002-10-25 2003-10-14 月経困難症の治療用トリアゾール化合物

Country Status (11)

Country Link
EP (1) EP1558598B1 (enExample)
JP (1) JP2006506380A (enExample)
AT (1) ATE367386T1 (enExample)
AU (1) AU2003267791A1 (enExample)
BR (1) BR0315676A (enExample)
CA (1) CA2502932A1 (enExample)
DE (1) DE60315062T2 (enExample)
ES (1) ES2287508T3 (enExample)
GB (1) GB0224919D0 (enExample)
MX (1) MXPA05004305A (enExample)
WO (1) WO2004037809A1 (enExample)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010514795A (ja) * 2006-12-28 2010-05-06 メタボレックス， インコーポレイテッド 糖尿病および代謝障害を処置するためのヘテロ環式受容体アゴニスト
JP2015500220A (ja) * 2011-12-02 2015-01-05 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ピペリジン誘導体、その医薬組成物及び使用
JP2017510645A (ja) * 2014-03-28 2017-04-13 アゼヴァン ファーマスーティカルズ，インコーポレイテッド 神経変性疾患を治療するための組成物および方法
US10292983B2 (en) 2016-08-03 2019-05-21 Cymabay Therapeutics, Inc. Oxymethylene aryl compounds for treating inflammatory gastrointestinal diseases or gastrointestinal conditions

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE349449T1 (de) * 2003-02-19 2007-01-15 Pfizer Für die therapie geeignete triazolverbindungen
GB0317227D0 (en) * 2003-07-23 2003-08-27 Pfizer Ltd Treatment of male sexual dysfunction
GB0325021D0 (en) * 2003-10-27 2003-12-03 Pfizer Ltd Therapeutic combinations
US7745630B2 (en) 2003-12-22 2010-06-29 Justin Stephen Bryans Triazolyl piperidine arginine vasopressin receptor modulators
EP2316458A1 (en) * 2004-09-20 2011-05-04 Xenon Pharmaceuticals Inc. Pyridazine derivatives for inhibiting human stearoyl-coa-desaturase
WO2006101521A2 (en) 2004-09-20 2006-09-28 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors
US8071603B2 (en) 2004-09-20 2011-12-06 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-CoA desaturase inhibitors
AP2007004047A0 (en) 2005-01-20 2007-06-30 Pfizer Ltd Substituted triazole derivatives as oxtocin antagonists
EP1877399A1 (en) * 2005-04-26 2008-01-16 Pfizer Limited Triazole derivatives as vasopressin antagonists
EP1885713A1 (en) 2005-05-18 2008-02-13 Pfizer Limited 1, 2, 4 -triazole derivatives as vasopressin antagonists
JP2009513563A (ja) 2005-06-03 2009-04-02 ゼノン・ファーマシューティカルズ・インコーポレイテッド ヒトのステアロイル−ＣｏＡデサチュラーゼ阻害剤としてのアミノチアゾール誘導体
EP1958631A1 (en) * 2007-02-14 2008-08-20 AEterna Zentaris GmbH Novel triazole derivatives as ligands of G-protein coupled receptors
CA2693169C (en) 2007-07-19 2016-01-12 Metabolex, Inc. N-linked heterocyclic receptor agonists for the treatment of diabetes and metabolic disorders
US8288371B2 (en) 2007-10-05 2012-10-16 Pharmacopeia, Llc Ortho pyrrolidine, benzyl-substituted heterocycle CCR1 antagonists for autoimmune diseases and inflammation
EP2483281B1 (en) 2009-10-01 2014-06-04 Cymabay Therapeutics, Inc. Substituted tetrazol-1-yl-phenoxymethyl-thiazol-2-yl-piperidinyl-pyrimidine salts
CA2802541A1 (en) 2010-06-23 2011-12-29 Metabolex, Inc. Compositions of 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine
EP2587919B1 (en) 2010-07-01 2017-12-13 Azevan Pharmaceuticals, Inc. Methods for treating post traumatic stress disorder
US9006450B2 (en) * 2010-07-01 2015-04-14 Boehringer Ingelheim International Gmbh Compounds, pharmaceutical compositions and uses thereof
IL273228B2 (en) 2017-09-15 2025-04-01 Azevan Pharmaceuticals Inc Preparations and methods for treating brain injury
WO2019169193A1 (en) 2018-03-01 2019-09-06 Annapurna Bio Inc. Compounds and compositions for treating conditions associated with apj receptor activity
US12479816B2 (en) 2019-02-08 2025-11-25 University of Pittsburgh—of the Commonwealth System of Higher Education 20-HETE formation inhibitors
CN116194441A (zh) * 2020-07-23 2023-05-30 豪夫迈·罗氏有限公司 作为加压素受体v1 a拮抗剂的环己基取代的三唑

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE574944C (de) * 1932-02-14 1933-04-21 Schering Kahlbaum Ag Verfahren zur Darstellung von 3, 4, 5-trisubstituierten 1, 2, 4-Triazolen
WO2001058880A1 (en) * 2000-02-08 2001-08-16 Yamanouchi Pharmaceutical Co., Ltd. Novel triazole derivatives
EP1293503A4 (en) * 2000-05-19 2008-04-02 Astellas Pharma Inc Triazole derivatives

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010514795A (ja) * 2006-12-28 2010-05-06 メタボレックス， インコーポレイテッド 糖尿病および代謝障害を処置するためのヘテロ環式受容体アゴニスト
US9737537B2 (en) 2006-12-28 2017-08-22 Cymabay Therapeutics, Inc. Heterocyclic receptor agonists for the treatment of diabetes and metabolic disorders
US9925189B2 (en) 2006-12-28 2018-03-27 Cymabay Therapeutics, Inc. Heterocyclic receptor agonists for the treatment of diabetes and metabolic disorders
JP2015500220A (ja) * 2011-12-02 2015-01-05 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ピペリジン誘導体、その医薬組成物及び使用
JP2017510645A (ja) * 2014-03-28 2017-04-13 アゼヴァン ファーマスーティカルズ，インコーポレイテッド 神経変性疾患を治療するための組成物および方法
JP2022116001A (ja) * 2014-03-28 2022-08-09 アゼヴァン ファーマスーティカルズ，インコーポレイテッド 神経変性疾患を治療するための組成物および方法
JP7255967B2 (ja) 2014-03-28 2023-04-11 アゼヴァン ファーマスーティカルズ，インコーポレイテッド 神経変性疾患を治療するための組成物および方法
US10292983B2 (en) 2016-08-03 2019-05-21 Cymabay Therapeutics, Inc. Oxymethylene aryl compounds for treating inflammatory gastrointestinal diseases or gastrointestinal conditions

Also Published As

Publication number Publication date
EP1558598A1 (en) 2005-08-03
ES2287508T3 (es) 2007-12-16
MXPA05004305A (es) 2005-08-03
AU2003267791A1 (en) 2004-05-13
EP1558598B1 (en) 2007-07-18
DE60315062T2 (de) 2008-04-10
WO2004037809A1 (en) 2004-05-06
ATE367386T1 (de) 2007-08-15
GB0224919D0 (en) 2002-12-04
DE60315062D1 (de) 2007-08-30
BR0315676A (pt) 2005-09-06
CA2502932A1 (en) 2004-05-06

Similar Documents

Publication Publication Date Title
JP2006506380A (ja) 月経困難症の治療用トリアゾール化合物
US7084145B2 (en) Triazole compounds useful in therapy
JP5261575B2 (ja) 化学化合物
JP4901102B2 (ja) プロテインキナーゼモジュレーターおよびその使用方法
JPWO1999005138A1 (ja) 複素環式化合物及びそれを有効成分とする抗腫瘍剤
KR20070007867A (ko) 선택된 ｃｇｒｐ 길항제, 이의 제조방법 및 약제로서의이의 용도
KR20080048041A (ko) 디아릴아민-함유 화합물 및 조성물, 및 ｃ-ｋｉｔ 수용체의조절제로서의 그의 용도
WO2009106980A2 (en) Indazole derivatives
JPWO2000004014A1 (ja) 抗腫瘍活性を有するピリミジン誘導体
JP2007534740A (ja) バソプレッシンＶ１ａ受容体の阻害剤としての３−ヘテロシクリル−４−フェニル−トリアゾール誘導体
JP2004513946A (ja) ドーパミンｄ３受容体のモジュレーターとして有用なテトラヒドロベンズアゼピン誘導体（抗精神病剤）
AU2006213634A1 (en) Substituted bis aryl and heteroaryl compounds as selective 5HT2A antagonists
TW201326143A (zh) Ｇ蛋白偶合ｍａｓ受體之調節劑及與其相關病症之治療
CA3105602A1 (en) Biaryl ether-type quinazoline derivatives
NZ289498A (en) Piperidinylpiperazine derivatives such as various piperidinylpiperazinylacetylphenoxy acetic acid derivatives, pharmaceutical compositions
BR112018008204B1 (pt) Composto, composição farmacêutica, e, método para tratamento de distúrbios associados com irregularidades da transmissão de sinal glutamatérgico e de distúrbios do sistema nervoso central
CA2524274A1 (en) 4-bromo-5-(2-chloro-benzoylamino)-1h-pyrazole-3-carboxylic acid (1-(aminocarbonyl)eth-1-yl) amide derivatives and related compounds as bradykinin b1 receptor antagonists for the treatment of inflammatory diseases
CZ301695B6 (cs) Deriváty N-triazolylmethylpiperazinu jako antagonistické látky neurokininových receptoru, jejich výroba a léciva
CN101272783B (zh) 作为大麻素cb1受体的激动剂的(吲哚-3-基)杂环衍生物
KR100750028B1 (ko) 치료에 유용한 트리아졸 화합물
EP2635567B1 (en) Indole derivatives
CN116870016B (zh) 杂芳环化合物及其医药用途
JP7385852B2 (ja) Ｐ２ｘ３受容体のアンタゴニストとしてのｎ－カルボキサミドピラゾリン系誘導体及びその使用
KR20180050408A (ko) 국부 약물 전달용의 비스테로이드성 글루코코르티코이드 수용체 조절제
WO2020181026A1 (en) Compounds for treating neurodegenerative diseases and cancers

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20061012

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20061012

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20071009

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20071009

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20071128